UBS, Jefferies, and BofA Cut Price Targets on Avantor (AVTR)

Avantor, Inc. (NYSE:AVTR) is one of the

. On February 12, UBS cut its price target on Avantor, Inc. (NYSE:AVTR) from $13 to $10.50 and maintained its Neutral rating. UBS noted that the company’s 2026 guidance came in below expectations. However, the research firm noted that Avantor, Inc. (NYSE:AVTR) has taken some “encouraging” steps.

On February 12, Jefferies also lowered its price target on Avantor, Inc. (NYSE:AVTR) from $9 to $8 and kept its Underperform rating. According to Jefferies, fiscal 2026 guidance was disappointing, even when expectations were not high. The research firm added that management’s outlook appeared to be “neither conservative nor aggressive.”

A day earlier, on February 11, BofA Securities reduced its price target on Avantor, Inc. (NYSE:AVTR) from $13 to $11 and maintained a Neutral rating on the stock after the company’s Q4 earnings call.

After the call, the stock fell during intraday trading as investors reacted to weaker-than-expected fiscal 2026 guidance. BofA Securities pointed out that there is still limited visibility into a potential recovery, noting that management did not provide a clear path for improvement in late 2026 or beyond.

Avantor, Inc. (NYSE:AVTR) is a leading life science tools company and a global provider of mission-critical products and services to customers in the biopharma, healthcare, education, government, and advanced technologies and applied materials industries.

While we acknowledge the potential of AVTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

.